Given the limited treatment options for patients with advanced HER2-positive (HER2+) solid tumors, recent regulatory approvals in the US and Europe have brought hope for many individuals in this patient population. The anticipated expansion of potential approvals in other regions globally underscores the need for clinicians worldwide to understand the importance of integrating routine molecular profiling into clinical practice to identify actionable biomarkers and tailor therapy accordingly. Other clinical protocols that would ensure accurate treatment selection include effective utilization of molecular tumor boards, which would enhance collaboration among the multidisciplinary team and lead to optimal patient outcomes. In this broadcast, expert faculty will review the most recent data supporting the use of HER2-directed therapies, how to use molecular profiling to identify patients for whom these treatments are appropriate, and best practices for collaboration among the multidisciplinary team.
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity.
